The Daily Fuckup

By April 7, 2020, President Donald Trump was still talking about hydroxychloroquine as though sheer repetition could do the work of evidence. For days, he had been elevating the malaria drug as a possible treatment for the coronavirus, and by this point it had become one of the administration’s most durable pandemic talking points. The problem was not that scientists were refusing to examine it. The problem was that the president kept speaking as if the question had already been settled, even though the evidence remained thin and the medical stakes were high. In the middle of a fast-moving public health emergency, that sort of confidence mattered because it gave the impression that a hunch, once spoken loudly enough from the Oval Office, could be turned into guidance for the entire country.

That approach carried risks that went far beyond partisan spin. Public health experts were warning that hydroxychloroquine had not been proven effective against COVID-19, and they were also cautioning that the drug could pose real dangers, especially when used without proper medical supervision. Even people open to studying it were making a basic distinction that Trump seemed unwilling to respect: investigation is not endorsement. He kept blurring that line, and in doing so he used the authority of the presidency to launder uncertainty into something that sounded more like a breakthrough than a speculative treatment. That is particularly dangerous in a crisis, because presidential language has a way of flattening nuance and giving the public the false impression that caution is merely hesitation. When the nation’s top elected official sounds sure before the science is, it can crowd out the very uncertainty that clinicians and researchers need to communicate clearly.

The White House also had a growing message problem, and it was not just cosmetic. Pandemic response depends on public discipline, and public discipline depends on a steady, accurate line from leaders. Instead, Trump was creating a moving target. Federal health officials, doctors, hospitals, and ordinary Americans were left trying to sort out the difference between a drug under study and a drug that the president seemed to be promoting. That confusion matters because it can invite self-medication, inspire false confidence, and muddy the waters for people who actually need medical advice grounded in clinical evidence. Trump’s enthusiasm gave the impression that hydroxychloroquine was on the verge of becoming a near-miracle, even though the data were still limited and the risks were still being assessed. In effect, the administration was having to manage the fallout from the president’s own remarks while also trying to guide the country through a worsening crisis. The result was less clarity than noise, and noise is exactly what a pandemic does not need.

The deeper institutional failure was that Trump’s fixation on hydroxychloroquine pulled attention away from the unglamorous work that actually mattered. Testing still needed to expand. Contact tracing still had to be built out. Protective equipment remained in short supply in many places. Hospitals were still preparing for a surge of patients, and public officials were still scrambling to make the basic machinery of response function at scale. Those are not headline-grabbing tasks, but they are the backbone of any effective pandemic strategy. Hydroxychloroquine, by contrast, was a flashy object that let Trump perform decisiveness without having to demonstrate command of the underlying public health effort. The more he talked it up, the more the administration had to defend, clarify, or contextualize his comments instead of staying focused on preparedness and mitigation. That is how a public health emergency gets dragged into the mud of personality politics: the country’s attention shifts from systems, capacity, and evidence to the president’s instincts, and then the instincts themselves become the story.

There was also a political cost to the way Trump kept pushing the drug. His pattern on hydroxychloroquine made him look eager to sell hope before it had been earned, and that is a dangerous position for any leader in a crisis. If the treatment later failed to deliver, his own rhetoric would hang around his neck. If it turned out to cause side effects, the insistence would look even worse. Either way, he was attaching his credibility to a medical gamble he did not appear to understand well enough to keep at arm’s length. Supporters and sympathetic voices around him amplified the hype, which only made the effort feel more like collective self-congratulation than careful policy. Trump was not merely commenting on an experimental treatment; he was turning it into a loyalty test inside his political ecosystem, where repetition and confidence could be mistaken for expertise. That may have suited a president who likes decisive language and dislikes uncertainty, but it did not make the country safer. It made the pandemic response look more reckless, more personalized, and more trapped in the habits of a president freelancing medicine from a podium than in the discipline of public health.